Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Inclusion Criteria: * Diagnosis of an ulcerative form of pyoderma gangrenosum confirmed by the investigator In addition, the subject must fulfill at least 3 of the following 6 criteria at screening: History of * Pathergy (ulcer occurring at the sites of trauma) * Personal history of inflammatory bowel disease or inflammatory arthritis * History of papule, pustule or vesicle that rapidly ulcerated Clinical examination (or photographic evidence) of * Peripheral erythema, undermining border, and tenderness at site of ulceration * Multiple ulcerations (at least 1 occurring on the lower leg) * Cribriform or "wrinkled paper" scar(s) at sites of healed ulcers Subject has a minimum of 1 evaluable ulcer (≥2 cm2) on the lower extremity at screening Exclusion Criteria: * Pyoderma gangrenosum target ulcer for more than 3 years before screening * Surgical wound debridement within the previous 2 weeks before screening * Use of intravenous antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 30 days before screening * Any drug treatment for pyoderma gangrenosum including corticosteroids (\>10 mg), intralesional steroids, cyclosporine A, biologicals and immunosuppressives (with the exception of antibiotics for wound superinfection) used within a time of 5 half-lives of the drug before screening